Cargando…

Swiss Recommendations for the Follow-Up and Treatment of Pulmonary Long COVID

INTRODUCTION: Emerging evidence suggests that long-term pulmonary symptoms and functional impairment occurs in a proportion of individuals following SARS-CoV-2 infection. Although the proportion of affected patients remains to be determined, physicians are increasingly being confronted with patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Funke-Chambour, Manuela, Bridevaux, Pierre-Olivier, Clarenbach, Christian F., Soccal, Paola M., Nicod, Laurent P., von Garnier, Christophe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339046/
https://www.ncbi.nlm.nih.gov/pubmed/34091456
http://dx.doi.org/10.1159/000517255
_version_ 1783733511934443520
author Funke-Chambour, Manuela
Bridevaux, Pierre-Olivier
Clarenbach, Christian F.
Soccal, Paola M.
Nicod, Laurent P.
von Garnier, Christophe
author_facet Funke-Chambour, Manuela
Bridevaux, Pierre-Olivier
Clarenbach, Christian F.
Soccal, Paola M.
Nicod, Laurent P.
von Garnier, Christophe
author_sort Funke-Chambour, Manuela
collection PubMed
description INTRODUCTION: Emerging evidence suggests that long-term pulmonary symptoms and functional impairment occurs in a proportion of individuals following SARS-CoV-2 infection. Although the proportion of affected patients remains to be determined, physicians are increasingly being confronted with patients reporting respiratory symptoms and impairment beyond the acute phase of COVID-19. In face of limited evidence, the Swiss Society for Pulmonology established a working group to address this area of unmet need and formulated diagnostic and treatment recommendations for the care of patients with pulmonary long COVID (LC). METHOD: The Swiss COVID Lung Study group and Swiss Society for Pulmonology (SSP) formulated 13 questions addressing the diagnosis and treatment of pulmonary LC. A survey within the SSP special interest groups involved in care of LC patients was conducted in Switzerland. A CORE process/Delphi-like process was used to formulate recommendations. Forty experienced pulmonologists replied to the first survey and 22 completed the second follow-up survey. Agreement of ≥70% consensus led to formulation of a recommendation. RESULTS: The participants in the survey reached consensus and formulated a strong recommendation for regarding the following points. Patients hospitalized for COVID-19 should have a pulmonary assessment including pulmonary function tests. Symptomatic subjects affected by COVID-19, including those with mild disease, should benefit from a pulmonary follow-up. Persistent respiratory symptoms after COVID-19 should be investigated by a pulmonary follow-up including plethysmography, diffusion capacity measurement, and blood gases analysis. Individuals having suffered from COVID-19 and who present with persistent respiratory symptoms should be offered a rehabilitation. Additional questions were given moderate or weak recommendations for. The panel did not reach sufficient consensus for pharmacological therapy (e.g., therapy specifically targeting lung fibrosis) to formulate recommendations for LC drug treatment. CONCLUSION: The formulated recommendations should serve as an interim guidance to facilitate diagnosis and treatment of patients with pulmonary LC. As new evidence emerges, these recommendations may need to be adapted.
format Online
Article
Text
id pubmed-8339046
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-83390462021-08-05 Swiss Recommendations for the Follow-Up and Treatment of Pulmonary Long COVID Funke-Chambour, Manuela Bridevaux, Pierre-Olivier Clarenbach, Christian F. Soccal, Paola M. Nicod, Laurent P. von Garnier, Christophe Respiration Guidelines INTRODUCTION: Emerging evidence suggests that long-term pulmonary symptoms and functional impairment occurs in a proportion of individuals following SARS-CoV-2 infection. Although the proportion of affected patients remains to be determined, physicians are increasingly being confronted with patients reporting respiratory symptoms and impairment beyond the acute phase of COVID-19. In face of limited evidence, the Swiss Society for Pulmonology established a working group to address this area of unmet need and formulated diagnostic and treatment recommendations for the care of patients with pulmonary long COVID (LC). METHOD: The Swiss COVID Lung Study group and Swiss Society for Pulmonology (SSP) formulated 13 questions addressing the diagnosis and treatment of pulmonary LC. A survey within the SSP special interest groups involved in care of LC patients was conducted in Switzerland. A CORE process/Delphi-like process was used to formulate recommendations. Forty experienced pulmonologists replied to the first survey and 22 completed the second follow-up survey. Agreement of ≥70% consensus led to formulation of a recommendation. RESULTS: The participants in the survey reached consensus and formulated a strong recommendation for regarding the following points. Patients hospitalized for COVID-19 should have a pulmonary assessment including pulmonary function tests. Symptomatic subjects affected by COVID-19, including those with mild disease, should benefit from a pulmonary follow-up. Persistent respiratory symptoms after COVID-19 should be investigated by a pulmonary follow-up including plethysmography, diffusion capacity measurement, and blood gases analysis. Individuals having suffered from COVID-19 and who present with persistent respiratory symptoms should be offered a rehabilitation. Additional questions were given moderate or weak recommendations for. The panel did not reach sufficient consensus for pharmacological therapy (e.g., therapy specifically targeting lung fibrosis) to formulate recommendations for LC drug treatment. CONCLUSION: The formulated recommendations should serve as an interim guidance to facilitate diagnosis and treatment of patients with pulmonary LC. As new evidence emerges, these recommendations may need to be adapted. S. Karger AG 2021-08 2021-06-04 /pmc/articles/PMC8339046/ /pubmed/34091456 http://dx.doi.org/10.1159/000517255 Text en Copyright © 2021 by S. Karger AG, Basel
spellingShingle Guidelines
Funke-Chambour, Manuela
Bridevaux, Pierre-Olivier
Clarenbach, Christian F.
Soccal, Paola M.
Nicod, Laurent P.
von Garnier, Christophe
Swiss Recommendations for the Follow-Up and Treatment of Pulmonary Long COVID
title Swiss Recommendations for the Follow-Up and Treatment of Pulmonary Long COVID
title_full Swiss Recommendations for the Follow-Up and Treatment of Pulmonary Long COVID
title_fullStr Swiss Recommendations for the Follow-Up and Treatment of Pulmonary Long COVID
title_full_unstemmed Swiss Recommendations for the Follow-Up and Treatment of Pulmonary Long COVID
title_short Swiss Recommendations for the Follow-Up and Treatment of Pulmonary Long COVID
title_sort swiss recommendations for the follow-up and treatment of pulmonary long covid
topic Guidelines
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339046/
https://www.ncbi.nlm.nih.gov/pubmed/34091456
http://dx.doi.org/10.1159/000517255
work_keys_str_mv AT funkechambourmanuela swissrecommendationsforthefollowupandtreatmentofpulmonarylongcovid
AT bridevauxpierreolivier swissrecommendationsforthefollowupandtreatmentofpulmonarylongcovid
AT clarenbachchristianf swissrecommendationsforthefollowupandtreatmentofpulmonarylongcovid
AT soccalpaolam swissrecommendationsforthefollowupandtreatmentofpulmonarylongcovid
AT nicodlaurentp swissrecommendationsforthefollowupandtreatmentofpulmonarylongcovid
AT vongarnierchristophe swissrecommendationsforthefollowupandtreatmentofpulmonarylongcovid